dalteparin has been researched along with Dermatoses in 22 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 7.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Dalteparin therapy was discontinued immediately, and anticoagulation was maintained with warfarin." | 5.32 | Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia. ( Kovacs, MJ; Payne, SM, 2003) |
| " Coumarin-induced skin necrosis was a recurrent feature during oral anticoagulation therapy, forcing her physicians to treat her with nadroparin (Fraxiparin) for only a few months." | 3.72 | Late onset of clinical symptoms and recurrent ecchymotic skin lesions in a 12-year-old girl with a severe double heterozygous protein C deficiency. ( Alhenc-Gelas, M; Corazza, F; Demulder, A; Ferster, A; Loop, M, 2004) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 3.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Rivaroxaban is a direct factor Xa inhibitor that prevents thrombus formation." | 2.82 | Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. ( Drabik, A; Eveslage, M; Gerss, J; Goerge, T; Kahle, B; Kreuter, A; Schneider, SW; Strölin, A; Weishaupt, C, 2016) |
| "In patients with chronic renal failure the risk of pathologic calcifications is raised due to elevated calcium-phosphorus products." | 1.32 | Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. ( Eich, D; Hunzelmann, N; Krieg, T; Scharffetter-Kochanek, K; Weihrauch, J, 2004) |
| "Dalteparin therapy was discontinued immediately, and anticoagulation was maintained with warfarin." | 1.32 | Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia. ( Kovacs, MJ; Payne, SM, 2003) |
| "Patients with chronic renal failure and hyperphosphatemia may be predisposed to develop calcinosis cutis." | 1.31 | Nadroparin-induced Calcinosis cutis in renal transplant recipients. ( Hilbrands, LB; Ruiter, DJ; van Haren, FM, 2001) |
| "These cases provide evidence of type IV hypersensitivity and the possibility of crossed-allergenicity among unfractionated heparin and low-molecular-weight heparins." | 1.30 | Delayed-type hypersensitivity to subcutaneous enoxaparin. ( Armentia, A; de la Fuente, R; Fernández, A; Martínez, C; Méndez, J; Sánchez, P; Sanchís, ME; Stolle, R; Vega, JM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Olde Bekkink, M | 1 |
| Diercks, GF | 1 |
| van den Berg, AP | 1 |
| Tack, CJ | 1 |
| Bulatovic, A | 1 |
| Schlieper, G | 1 |
| Stankovic-Popovic, V | 1 |
| Vujic, D | 1 |
| Floege, J | 1 |
| Dimkovic, N | 1 |
| Seront, B | 1 |
| Marot, L | 1 |
| Demoulin, N | 1 |
| Jadoul, M | 1 |
| Morelle, J | 1 |
| Pérez, DL | 1 |
| Peña-Romero, AG | 1 |
| Díaz-González, JM | 1 |
| Domínguez-Cherit, J | 1 |
| Nuno-Gonzalez, A | 1 |
| Calzado-Villarreal, L | 1 |
| Gutierrez-Pascual, M | 1 |
| Gamo-Villegas, R | 1 |
| Sanz-Robles, H | 1 |
| Sanchez-Gilo, A | 1 |
| Pinedo-Moraleda, F | 1 |
| Lopez-Estebaranz, JL | 1 |
| Loop, M | 1 |
| Ferster, A | 1 |
| Corazza, F | 1 |
| Alhenc-Gelas, M | 1 |
| Demulder, A | 1 |
| Eich, D | 1 |
| Scharffetter-Kochanek, K | 1 |
| Weihrauch, J | 1 |
| Krieg, T | 1 |
| Hunzelmann, N | 1 |
| Giorgini, S | 1 |
| Martinelli, C | 1 |
| Massi, D | 1 |
| Lumini, A | 1 |
| Mannucci, M | 1 |
| Giglioli, L | 1 |
| Wanic-Kossowska, M | 1 |
| Kozioł, L | 1 |
| Roszkowiak, B | 1 |
| Lacka, M | 1 |
| Frankiewicz, D | 1 |
| Mandel, M | 1 |
| van Haren, FM | 1 |
| Ruiter, DJ | 1 |
| Hilbrands, LB | 1 |
| Zhou, HW | 1 |
| Tan, C | 1 |
| Pasha, AK | 1 |
| McBane Ii, RD | 1 |
| Li, J | 1 |
| Inwald, G | 1 |
| Thomas, M | 1 |
| Neloska, L | 1 |
| Damevska, K | 1 |
| Pavleska, L | 1 |
| Weishaupt, C | 1 |
| Strölin, A | 1 |
| Kahle, B | 1 |
| Kreuter, A | 1 |
| Schneider, SW | 1 |
| Gerss, J | 1 |
| Eveslage, M | 1 |
| Drabik, A | 1 |
| Goerge, T | 1 |
| Scharf, Y | 1 |
| Hershkoviz, R | 1 |
| Tai, CY | 1 |
| Ierardi, R | 1 |
| Alexander, JB | 1 |
| Toll, A | 1 |
| Gallardo, F | 1 |
| Abella, ME | 1 |
| Fontcuberta, J | 1 |
| Barranco, C | 1 |
| Pujol, RM | 1 |
| Méndez, J | 1 |
| Sanchís, ME | 1 |
| de la Fuente, R | 1 |
| Stolle, R | 1 |
| Vega, JM | 1 |
| Martínez, C | 1 |
| Armentia, A | 1 |
| Sánchez, P | 1 |
| Fernández, A | 1 |
| Payne, SM | 1 |
| Kovacs, MJ | 1 |
| Peitsch, WK | 1 |
| Glorer, E | 1 |
| Dempfle, CE | 1 |
| Back, W | 1 |
| Bayerl, C | 1 |
| Goerdt, S | 1 |
| Moore, A | 1 |
| Lau, E | 1 |
| Yang, C | 1 |
| Mackool, B | 1 |
| Kuter, DJ | 1 |
1 trial available for dalteparin and Dermatoses
| Article | Year |
|---|---|
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Enoxaparin; Factor Xa Inhibitors; Female; Germany; Humans; Male; | 2016 |
21 other studies available for dalteparin and Dermatoses
| Article | Year |
|---|---|
A patient with cutaneous lesions after liver transplantation.
Topics: Adult; Anticoagulants; Calcinosis; Female; Humans; Injections, Subcutaneous; Liver Transplantation; | 2013 |
Iatrogenic calcinosis cutis after subcutaneous LMW-heparin administration in a hemodialysis patient.
Topics: Biopsy, Needle; Calcinosis; Female; Humans; Iatrogenic Disease; Immunohistochemistry; Injections, Su | 2013 |
The Case | Subcutaneous abdominal calcified nodules and severe hyperphosphatemia.
Topics: Abdomen; Adult; Anticoagulants; Biopsy; Calcinosis; Chelating Agents; Drug Substitution; Enoxaparin; | 2016 |
Nadroparin-induced skin necrosis: clinical manifestation of HIT-2 even in the absence of thrombocytopaenia.
Topics: Adult; Humans; Male; Nadroparin; Necrosis; Skin Diseases; Thrombocytopenia | 2016 |
An unusual adverse effect of nadroparin injections: Calcinosis cutis.
Topics: Adult; Amiodarone; Anticoagulants; Atrial Fibrillation; Biopsy; Calcinosis; Calcium; Enoxaparin; Hum | 2011 |
Late onset of clinical symptoms and recurrent ecchymotic skin lesions in a 12-year-old girl with a severe double heterozygous protein C deficiency.
Topics: Age of Onset; Anticoagulants; Child; Coumarins; DNA Mutational Analysis; Ecchymosis; Family Health; | 2004 |
Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins.
Topics: Anticoagulants; Calcinosis; Child; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Nadr | 2004 |
Iatrogenic calcinosis cutis following nadroparin injection.
Topics: Aged; Aged, 80 and over; Anticoagulants; Calcinosis; Humans; Iatrogenic Disease; Injections, Subcuta | 2005 |
[Calcified subcutaneous nodules in patients with chronic renal failure as a result of injections with nadroparin (Fraxiparine)].
Topics: Aged; Anticoagulants; Arteriosclerosis; Calcinosis; Female; Humans; Hypertension; Injections, Subcut | 1998 |
Nadroparin-induced Calcinosis cutis in renal transplant recipients.
Topics: Adult; Biopsy; Calcinosis; Calcium; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 2001 |
Acute Generalized Pustular Bacterid: An Uncommon Dermatosis That Commonly Presents With Acral Pustules.
Topics: Acute Generalized Exanthematous Pustulosis; Heparin, Low-Molecular-Weight; Humans; Psoriasis; Skin D | 2019 |
Heparin Skin Necrosis in Heparin-Induced Thrombocytopenia.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Injections; Necrosis; Skin Diseases; Thrombocytope | 2021 |
A Rare Case of Enoxaparin-Induced Skin Necrosis Without Thrombocytopenia.
Topics: Abdomen; Adult; Anticoagulants; Drug Eruptions; Enoxaparin; Female; Humans; Necrosis; Skin Diseases | 2019 |
Enoxaparin-induced Skin Necrosis.
Topics: Aged; Anticoagulants; Comorbidity; Diagnosis, Differential; Enoxaparin; Fatal Outcome; Female; Human | 2015 |
[Enoxaparin induced skin necrosis].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Humans; Necrosis; Skin; Skin Diseases | 2003 |
A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.
Topics: Anticoagulants; Arterial Occlusive Diseases; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-M | 2004 |
Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states.
Topics: Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Fo | 2005 |
Delayed-type hypersensitivity to subcutaneous enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Hypersensitivity, Delayed; Injections, Subcutaneou | 1998 |
Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia.
Topics: Antibodies; Dalteparin; Humans; Male; Middle Aged; Skin; Skin Diseases; Thrombocytopenia; Warfarin | 2003 |
[Cutaneous necroses mainly on the extremities].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Diagnosis, Differential; Extremities; Female; F | 2004 |
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Anticoagulants; Dalteparin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle | 2007 |